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Abstract.  Cell-substratum adhesion in the embryonic 
chicken nervous system has been shown to be media- 
ted in part by a  170,000-mol-wt polypeptide that is a 
component of adherons. Attachment of retinal cells to 
the 170,000-mol-wt protein is inhibited by the C~H3 
monoclonal antibody and by heparan sulfate (Cole, G. 
J., D. Schubert, and L. Glaser,  1985, J. Cell Biol., 
100:1192-1199).  In the present study we have demon- 
strated that the 170,000-mol-wt cin3 polypeptide is 
immunologically identical to the neural cell adhesion 
molecule N-CAM, and that the 170,000-mol-wt com- 
ponent of N-CAM is preferentially secreted by cells as 
a component of adherons. We have identified a 
monoclonal antibody, designated BIA3, that inhibits 
heparin binding to N-CAM and cell-to-substratum 
adhesion. A 25,000-mol-wt heparin (heparan sulfate)- 
binding domain of N-CAM has been identified by 
limited proteolysis, and this fragment promotes cell 
attachment when bound to glass surfaces. The frag- 
ment also partially inhibits cell binding to adherons 
when bound to retinal cells, and the BjA3 monoclonal 
antibody inhibits retinal cell attachment to substrata 
composed of intact N-CAM or the heparin-binding 
domain. These data are the first evidence that N-CAM 
is a multifunctional protein that contains both cell- 
and heparin (heparan sulfate)-binding domains. 
STABLISHMENT of neural connections during embryo- 
genesis  depends  upon  a  variety of cell  recognition 
processes, which include cell-cell and cell-matrix in- 
teractions. Cell-cell adhesion has been particularly well stud- 
ied in the developing nervous system, and several macromol- 
ecules  that play an integral role  in these interactions have 
been identified ( 10, 12-14,  17, 23, 33). The best characterized 
cell adhesion molecule is N-CAM (7, 27), which mediates cell 
adhesion processes via a homophilic binding mechanism (28). 
Although these studies have provided insight into the mech- 
anisms governing interactions between neural cells, a paucity 
of information exists regarding how neural cells interact with 
their substratum during neural development. 
Cell-substratum adhesion involving fibroblast-like cells has 
been well characterized, with fibronectin being the molecular 
component primarily responsible  for this process  (15, 37). 
The interaction of fibroblasts with fibronectin in the extracel- 
lular matrix has been shown to depend upon heparan sulfate 
proteoglycan (25), and  the  binding  of heparan  sulfate to 
fibronectin was proposed to induce a conformational change 
in  the  protein  (16).  It has  recently been  demonstrated by 
circular dichroism that heparin does induce a conformational 
change in fibronectin (21). After this conformational change 
fibronectin interacts with the cell surface with a higher affinity 
(16), as measured by biological  cell-binding  activity. These 
data, therefore, suggest that the interaction between heparan 
sulfate and fibronectin may modulate the biological activity 
of fibronectin. A role  for fibronectin in neuronal cell inter- 
actions has also been suggested, as neural crest cell migration 
is a  fibronectin-dependent process  (2). In addition, neurite 
outgrowth in vitro has been shown to involve the heparin- 
binding domain of fibronectin (24). However, the precise role 
of fibronectin,  or  other  extracellular matrix  molecules  in 
neural  cell-substratum  interactions,  still  remains  unclear 
since these matrix molecules are not widely distributed in the 
developing central nervous system. 
Recent studies  by Schubert and his co-workers  (29, 31) 
demonstrated that embryonic chick neural retina cells release 
macromolecular components,  termed  adherons,  into  their 
culture medium. Adherons promote cell-substratum 1  attach- 
ment when adsorbed onto tissue culture plastic (31), and this 
cell  attachment can  be  inhibited by heparin  and heparan 
sulfate (29, 31). The latter is presumed to be the physiologi- 
cally important ligand since heparan sulfate occurs on the 
surface of  retinal cells (29), and an antiserum produced against 
a cell surface heparan sulfate proteoglycan has been shown to 
inhibit cell-adheron binding (29). However,  heparin can be 
used as a  functional analogue of heparan sulfate since it is 
closely related in structure to heparan sulfate. 
We  have  previously reported  the  isolation  of a  mono- 
clonal antibody (MAb), 2 designated CIH3, which recognizes a 
170,000-mol-wt polypeptide that is a component of adherons 
In these studies, cell-substratum adhesion will refer to cell attachment to an 
appropriate substratum. The substrata we will refer to are adherons, which are 
produced  by  retinal  cells in  vitro,  or  identified proteins which  have  been 
covalently coupled to a glass surface. 
2 Abbreviations  used in this paper:. MAb, monoclonal antibody. N-CAM, neural 
cell adhesion molecule. 
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and the purified antigen, when linked to an inert surface such 
as glass,  promotes cell attachment (5). We demonstrated that 
heparan sulfate inhibits the binding of retinal cells to 170,000- 
mol-wt protein and that heparan sulfate binds to the 170,000- 
mol-wt protein and induces a conformational change in the 
molecule (6). Recent studies in several laboratories have sug- 
gested that the interaction of neural cells with the extracellular 
matrix glycoprotein laminin is required for neurite outgrowth 
(19,  34), and that the heparin-binding domain of laminin is 
capable of mediating this effect (8). Together, these observa- 
tions raise the possibility that heparan sulfate-protein inter- 
actions  are  important  for  cell-substratum  adhesion  in  the 
developing nervous system. We have therefore used MAbs to 
identify the molecular domain in the  170,000-mol-wt  CIH3 
polypeptide which is responsible for heparan sulfate binding. 
In  the  present  study  we  show  that  after  cleavage  of  the 
170,000-mol-wt  protein  with  subtilisin  protease,  a  25,000- 
mol-wt fragment  is retained  on  a  heparin-agarose column. 
This fragment, when covalently coupled to glass,  promotes 
the attachment of retinal cells. The fragment also acts as an 
inhibitor of cell attachment to adherons when bound to retinal 
cells before the adhesion assay. 
We had previously reported that the 170,000-mol-wt C~H3 
protein  was  unrelated  to  N-CAM  since  N-CAM  was  not 
detected in adherons (5).  This conclusion was based on ex- 
periments in which an anti-N-CAM MAb (224-1A6-A1)  did 
not bind  to  intact  adherons or immunoprecipitate  labeled 
protein from solubilized adherons (5).  Two recent observa- 
tions prompted our reexamination of this problem. J. Covault 
and  J.  Sanes  (personal  communication)  demonstrated  by 
immunoblotting that the CIH3 MAb binds immunopurified 
N-CAM.  In addition, a  recent description of changes in  N- 
CAM  during  retinal  development  (9)  parallel  our previous 
description of the C~ Ha antigens; i.e., the low molecular weight 
form  (140,000-mol-wt)  appears  in  development  before  the 
high molecular weight form (170,000-mol-wt). Previous stud- 
ies regarding  N-CAM  had  implied  that  the high  molecular 
weight form appeared first in development. Our present stud- 
ies  indicate  that  the  anti-N-CAM  MAb  recognizes signifi- 
cantly less protein in conditioned medium from retinal cul- 
tures than does the CIH3 MAb, and this reduced sensitivity 
may account for our previous failure to detect immunopre- 
cipitable  protein  in  adherons with  this anti-N-CAM  MAb. 
Nevertheless,  our observations reported below indicate that 
the Cj H3 epitope is present on the majority of retinal N-CAM 
molecules as defined by an anti-N-CAM antibody, and also 
suggest that heparan sulfate-N-CAM  interactions are likely 
to be important during neuronal development. 
Materials and Methods 
Production of  Antibodies 
The  preparation  and  characterization of the C~H3 MAb has been described 
previously (3)  and  was obtained by immunizing rats with emb~'onic day 9 
retinal cells. The B~A3 MAb was produced by immunizing BALB/c mice with 
immunopurified  170,000-mol-wt protein, and screening hybridomas using a 
dot-blot assay (5). Anti-N-CAM MAb was a generous gift of Dr. David Gottlieb 
(Washington  University, St.  Louis) (36)  and  was obtained  by  immunizing 
BALB/c mice with emb~'onic day 9 retinal cells. Anti-heparan sulfate proteo- 
glycan antiserum was a generous gift of Dr. David Schubert (The Salk Institute, 
La Jolla, CA). 
Preparation of  Adherons 
We prepared adherons from  retinal cell cultures as described previously (5). 
Emb~'onie day  11  chick  retinas were  mechanically dissociated with  a  fire- 
polished pipette  and  incubated  for  18  h  at  370C  in  serum-free  DulbeccCs 
modified  Eagle's medium  containing transferrin,  insulin,  progesterone,  and 
putrescine (I).  Conditioned medium  was then  processed as described (5)  to 
yield adherons.  We  have also demonstrated  that  adherons are  produced  in 
serum-containing medium, and thus may represent normally secreted retinal 
cell components. 
Cell-Substratum Adhesion Assays 
To  assay adhesion  of neural  retina cells, day  I 1 retinas were mechanically 
dissociated and metabolically labeled for 2 h with 5 uCi/ml of [35S]melhionine 
(translation grade, New England Nuclear, Boston, MA). Labeled cells were then 
washed twice with Earle's balanced salt solution (EBSS) containing 0.2% bovine 
serum albumin (BSA), and 0.2-ml aliquots were incubated with adheron-coated 
dishes or 0. l-ml aliquots were incubated with glass scintillation vials that had 
been  coated  with  20  ug/ml  of  170,000-mol-wt  protein  or  3  ug/ml  of the 
heparin-binding domain.  Glass vials were coated  with protein  according to 
published  procedures  (5).  Assays using glass vials contained  125  ug/ml  of 
chondroitin sulfate in the medium, which was used to decrease nonspecific cell 
attachment (6).  After a  I h  incubation of cells with dishes, non-attached cells 
were removed by swirling the dishes and vacuum aspiration. Bound cells were 
solubilized in Triton X-100, and isotope content was measured. 
The  effect  of antibodies on  cell-substratum  adhesion  was  examined  as 
previously described (5.  6).  The effect of the heparin-binding domain of the 
170,000-mol-wt  protein  on  cell  attachment  was  determined  by  incubating 
labeled retinal cells for  1 h  at 4°C with  10 ug/ml of the fragment. The cells 
were then washed twice by centrifugation and added to vials coated with the 
170,000-mol-wt  protein or to adheron-coated dishes. 
Preparation of  Heparin-binding Domain 
A heparin-binding domain of the 170,000-mol-wt CIH3 polypeptide was iden- 
tified by digesting 300 ,ag of partially purified protein (isolated as described in 
references 5 and 6) with a  1:50 enzyme-to-substrate ratio of subtilisin protease 
(Sigma Chemical Co.,  St.  Louis,  MO) for 45  min at 37°C.  The reaction was 
terminated by the addition of phenylmethylsulfonyl fluoride (to 0.3 mM) and 
1,000 U ofaprotinin. The sample was then incubated with heparin-agarose for 
2 h at room temperature, in 15 mM NaCI.  10 mM K2HPO4,  10 mM KH2PO4. 
pH  7.4.  The heparin-agarose was then packed into a column and eluted with 
3  column  volumes of incubation  buffer.  Bound  protein  was  eluted with  3 
column volumes of 1 M  NaCI. The fractions were then desalted and concen- 
trated  in  Amicon  microconcentrators  (Amicon  Corp.,  Danvers,  MA).  and 
analyzed by polyacrylamide gel electrophoresis and immunoblotting. 
Immunoprecipitation and Immunoblotting Analysis 
of  Antigens 
The analysis of immunopurified N-CAM.  170,000-mol-wt CjH3  protein,  or 
heparin-binding fractions by immunoblotting was as described previousl.~  (3, 
6).  Briefly,  proteins  were  separated  by  polyacry'lamide gel  eleetrophoresis, 
transferred to  nitrocellulose, and  reacted with MAbs.  Antibody binding v, as 
visualized by reaction with Vectastain ABC reagents (Vector Laboratories. Inc., 
Burlingame. CA). 
Immunoprecipitation of metabolically labeled retinal cell proteins was ac- 
cording to  published methods (3).  Briefly, day  7  retinas were  mechanically 
dissociated and labeled with  100 uCi/ml of [35S]methionine for  1-2  h.  Cells 
were then homogenized in RIPA buffer (3) and incubated with MAbs and S. 
aurett.s  cells coated with goat anti-rat IgG (Cappel Laboratories. Cochran~ille, 
PA). Conditioned medium was also immunoprecipitated with MAbs. and this 
invol~ed adding an equal volume of RIPA buffer,  adjusting the  medium to 
0.2%  SDS.  and  heating to  60°C  for  10  min.  This  protocol  results  in  the 
solubilization of adheron complexes in the medium, and thus cleaner immu- 
noprecipitations of the  170,000-mol-wt or N-CAM  proteins, lmmunoprecipi- 
tated proteins were analyzed by electrophoresis on 6% pol,,ac~ lamide gels, and 
radioactive proteins were visualized by fluorography. 
Results 
Comparison of  N-CAM and the 170,O00-mol-wt 
C1H3 Protein 
Cell-cell adhesion in the developing nervous system has been 
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acterized cell adhesion  molecule (7,  27).  Like N-CAM,  the 
170,000-moi-wt C~H3 protein mediates cell interactions via a 
homophilic  binding  mechanism  (5,  6,  28),  although  it  is 
apparent that the binding of beparan sulfate to the  170,000- 
mol-wt protein is also necessary for its function (6). The C~H3 
polypeptide also is similar in  molecular weight to  N-CAM, 
exhibits a  developmental regulation pattern identical to that 
of N-CAM in  chick retina, and has been  shown  to bind to 
immunopurified N-CAM (Covault, J., and J. Sanes, personal 
communication). It therefore appeared possible to us that the 
CtH3 protein might constitute a  subset of N-CAM molecules 
(35),  and  this possibility was  investigated further  using im- 
munoprecipitation and immunoblotting techniques. 
An  initial approach  used  to  demonstrate  immunological 
identity between N-CAM and the CjH3 antigen was immu- 
noblotting of the immunopurified proteins. As shown in Fig. 
1,  the  CIH3  MAb binds to  both  immunopurified  170,000- 
mol-wt protein and  N-CAM, and an  MAb against N-CAM 
binds the  170,000-mol-wt protein. Although the staining pat- 
terns are similar, they are not identical. It therefore appears 
that  the  two  polypeptides are  immunologically similar, al- 
though  it is possible that the  170,000-mol-wt protein repre- 
Figure 1. lmmunoblotting of immunopurified 170,000-mol-wt C~H3 
protein and N-CAM. 5-ttg aliquots of N-CAM immunopurified with 
the CjH3 MAb (a and c) or anti-N-CAM MAb (b) were separated on 
a  7%  polyacrylamide gel, transferred  to nitrocellulose,  and reacted 
with C~ H3 MAb (a and b) or anti-N-CAM MAb (c), Antibody  binding 
was visualized  as described under Materials and  Methods.  The N- 
CAM protein blotted with anti-N-CAM MAb in lane c was electro- 
phoresed on a different gel than the protein in lanes a and b. 
t:tgure 2.  Immunoprecipitation of metabolically labeled retinal cell 
proteins. Embryonic day 7 retinal cells were labeled with [35S]methi- 
onine in Spinner culture for 2 h as described under Materials and 
Methods. Labeled cells were then centrifuged and washed twice. Cells 
were then homogenized in RIPA buffer and incubated overnight at 
4"C with monoclonal antibodies. Immunoprecipitated proteins were 
isolated by incubating with Staphylococcus  attreus cells coated with 
goat anti-rat lgG. Labeled proteins were also immunoprecipitated 
from  conditioned medium that was diluted  1:1  with  RIPA buffer, 
adjusted to 0.2% SDS, and heated to 60°C for 10 min to solubilize 
adheron complexes.  Immunoprecipitated proteins were analyzed by 
electrophoresis on  6%  polyacrylamide gels and were  visualized  by 
fluorography.  Lanes: a, cell extract immunoprecipitated with  CjH3 
MAb: b. cell extract immunoprecipitated with anti-N-CAM MAb; c, 
incubation with anti-N-CAM after immunoprecipitation with CjH3 
MAb: d, immunoprecipitation of cell extract with B~A3 MAb. Lanes 
e-g show immunoprecipitation of medium with B~A3 (e), C~H3 (f), 
and  anti-N-CAM  MAbs (g).  It  should  be  noted  that  equivalent 
amounts  of radioactivity were  not  loaded  in  each  lane,  and  the 
difference  in  reactivity between  the  MAbs is  slight.  The  starting 
material for lane c was similar to lane b,  and thus the majority of 
radioactivity is removed by the CjH3 MAb before immunoprecipita- 
tion with anti-N-CAM MAb. 
sents a  unique subpopulation of N-CAM molecules (35). To 
test this possibility, embryonic day 7 retinal cells were pulse- 
labeled for 2 h with [35S]methionine and immunoprecipitated 
with  the C~H3 and  anti-N-CAM MAbs.  In Fig. 2  it can  be 
seen that the C~H3 MAb immunoprecipitates both  170,000- 
and  140,000-mol-wt proteins from a cell extract, but only the 
170,000-mol-wt protein is immunoprecipitated from  condi- 
tioned medium. The anti-N-CAM MAb also reacts with both 
molecular weight polypeptides in cell extracts and immuno- 
precipitates a  170,000-mol-wt protein from conditioned me- 
dium. Our data would appear to suggest that the two proteins 
may be immunologically identical, since if labeled retinal cell 
405  Cole  and Glaser  Heparin-binding Domain from N-CAM proteins are immunoprecipitated with CIH3 MAb, followed 
by immunoprecipitation with anti-N-CAM MAb, most of the 
N-CAM molecules are removed by the C~H3 MAb (Fig. 2). 
We have previously shown that the  170,000-mol-wl CjH~ 
protein binds heparin, and thus this is the first evidence that 
N-CAM  is a  multifunctional  protein,  containing  both cell- 
and heparin-binding domains. These data also show that early 
embryonic chick retinal cells  synthesize the  170,000-mol-wt 
form of N-CAM, although a  recent study by Friedlander et 
al.  (9)  demonstrated  that  by  immunoblotting  only  the 
140,000-mol-wt form of the protein is detected in day 7 retinal 
cells. Friedlander et al. (9) also demonstrated that early retina 
cultures  synthesize  primarily  the  140,000-mol-wt  N-CAM 
molecules, although they used long-term labeling protocols in 
the studies. We have used short pulse labeling in our studies 
and  also have shown  that  most of the  170,000-mol-wt  N- 
CAM is secreted by the cells. These data are thus in agreement 
with our previous findings that the synthesis of the  170,000- 
mol-wt protein can be induced prematurely in vitro (3).  In 
addition,  these studies indicate that the  170,000-mol-wt N- 
CAM  component is preferentially released into  the  culture 
medium, which may suggest that this N-CAM component is 
associated with the extracellular matrix. 
Identification  of the Heparin-binding Domain 
of  N-CAM 
As stated above, we have previously shown that the  170,000- 
mol-wt C jH3 protein (designated hereafter as N-CAM) specif- 
ically binds [3H]heparin, indicating that it contains a heparin- 
binding domain (6). Heparan sulfate also inhibits the attach- 
ment of retinal  cells to glass surfaces coated with N-CAM, 
and an antiserum directed against a retinal cell surface hep- 
aran sulfate proteoglycan has a similar effect (6). These data 
therefore suggest that the heparin-binding domain of the N- 
CAM protein is functionally important for retinal cell attach- 
ment to the extracellular matrix. In the present study we were 
interested in identifying the molecular domain in the N-CAM 
protein  responsible  for  heparin  binding,  and  determining 
whether MAbs that recognize this domain could inhibit cell- 
substratum adhesion.  Although heparan sulfate can be con- 
sidered the physiologically important ligand, heparin is closely 
related in structure to heparan sulfate and can be used as a 
functional  analogue  of heparan  sulfate.  We  have therefore 
used heparin in these studies, although in the nervous system 
heparan sulfate is the relevant molecule. 
N-CAM protein was partially purified from detergent ex- 
tracts of embryonic day  14  chick brain  using  C~H3 MAb 
coupled to Sepharose 4B (5), and in the present experiments 
consists  of the  170,000-mol-wt  protein  and  several  lower 
molecular  weight  proteins  (Fig.  3a).  However,  only  the 
170,000-mol-wt protein  reacts with  any  of our  MAbs that 
bind to the molecule on an immunoblot (data not shown). 
This N-CAM protein is retained on a  heparin-agarose col- 
umn, although only 20% of the protein binds to the column 
(data not shown). These data confirm our previous observa- 
tions that the molecule possesses a heparin-binding domain. 
To identify the  molecular domain  responsible for heparin- 
binding, proteolytic digests of the N-CAM  protein were in- 
cubated with  heparin-agarose. We have previously demon- 
strated that digestion of the protein with subtilisin protease 
yielded a variety of fragments that reacted with the C~H3 MAb 
(6),  and  we  thus  chose  to  use  subtilisin  protease  in  these 
Figure 3. Identification of heparin-binding domain  from N-CAM. 
300  #g  of immunopurified  N-CAM was  digested with subtilisin 
protease ( 1:50 enzyme to substrate) as described under Materials and 
Methods and incubated with 0.5 ml of heparin-agarose. Unbound 
and bound fractions were collected as described, and aliquots were 
electrophoresed on a 9%  polyacrylamide gel, followed by staining 
with Coomassie Blue. (a) 20 ~zg of undigested N-CAM; (b) digested 
N-CAM before heparin-agarose chromatography; (c) unbound frac- 
tion: and (d) bound fraction. Only a 25,000-mol-wt fragment (de- 
noted by arrow) is retained on heparin-agarose. 
experiments. When N-CAM protein is incubated with subtil- 
isin protease for 45 min, several bands ranging in molecular 
weight from 70,000 to 25,000 are detected by Coomassie Blue 
staining  (Fig.  3b).  After  heparin-agarose  chromatography 
only the 25,000-mol-wt fragment is retained on the column 
(Fig.  3 d).  This fragment therefore appears to represent the 
heparin-binding domain of N-CAM. It should also be noted 
that almost all of the 25,000-mol-wt fragment obtained binds 
to heparin-agarose, in contrast to our experiment with intact 
N-CAM protein, which binds heparin-agarose poorly. These 
results may be explained by the possibility that the heparin- 
binding domain is not exposed on all N-CAM molecules in 
solution, particularly since N-CAM is known to aggregate in 
solution. This may account for only 20% of the intact protein 
binding heparin-agarose, whereas most of  the isolated domain 
is bound by the heparin-agarose column. 
To confirm that the  25,000-mol-wt heparin-binding frag- 
ment was derived from the N-CAM protein, and to determine 
the precise role of this structural domain in the function  of 
the protein, we analyzed this fragment using immunoblotting. 
As shown in Fig. 4b, the CIH3 MAb does not react with this 
fragment, which  suggests  that the  C1H3 MAb  inhibits  cell- 
substratum adhesion by interacting with another functional 
domain. However, the C~H3 MAb also does not bind to any 
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ing domain with anti-N-CAM  MAbs. Ali- 
quots of unbound and bound fractions ob- 
tained  by  heparin-agarose  chromatogra- 
phy, as described in Fig. 3, were separated 
on a 9% polyacrylamide gel and transferred 
to  nitrocellulose.  The  nitrocellulose  blot 
was then incubated with C~H3 MAb (a and 
b) or B~A3 MAb (c and  d)  as described 
under Materials and Methods.  Proteolytic 
fragments not retained on heparin-agarose 
are shown in lanes a and c; the 25,000-mol- 
wt fragment  is present  in lanes  b  and  d. 
Note that only the B~A3 MAb reacts with 
the heparin-binding domain. Lanes e andf 
show the  results of immunoblotting with 
B~A3 MAb of the heparin-binding  domain 
isolated  from  N-CAM  purified  with  the 
CtH3 MAb (50 ~g starting material, lane e) 
or an  anti-N-CAM  MAb (15  ug starting 
material,  lane f).  The arrow  denotes  the 
25,000-mol-wt fragment. These results con- 
firm that N-CAM and the 170,000-mol-wt 
CtH3 protein are immunologically  related. 
Molecular  weight  markers  are  indicated; 
DF, dye front of the gel. 
components  that  are  not  retained  by  the  heparin-agarose 
column (Fig. 4a). These data therefore imply that the CIH3 
epitope does not survive the conditions used to generate the 
proteolytic fragments. This proposal is supported by a time- 
course digestion, which shows that the CjH3 MAb reacts with 
several  fragments  after  a  10-min  digestion,  but  under  the 
conditions  used  for  heparin-agarose  chromatography  the 
MAb does not recognize any proteolytic fragments (Fig. 5, a- 
c). 
We  have  generated  additional  MAbs  that  recognize  N- 
CAM, one of which, designated B~A3, reacts with an epitope 
distinct  from the C~H3 antigenic determinant.  As shown in 
Fig. 2, the BjA3 MAb immunoprecipitates proteins with mo- 
lecular weights identical to that of N-CAM. As shown in Fig. 
5, d-f, the BjA3 MAb reacts with a  65,000-mol-wt fragment 
that is obtained by proteolysis of N-CAM, and this fragment 
is  converted  to  a  25,000-mol-wt  fragment  with  prolonged 
proteolysis by subtilisin.  This MAb is therefore a  good can- 
didate for reacting with the heparin-binding domain and, as 
demonstrated in Fig. 4d, the BIA3 MAb binds to the 25,000- 
mol-wt heparin-binding fragment. It can also be seen in Fig. 
4,  e  and fthat  the  B~Aa MAb reacts with  a  25,000-mol-wt 
heparin-binding fragment obtained by digesting immunopu- 
rifled  N-CAM  (obtained  from  an  anti-N-CAM  column  as 
described in Fig.  1) with subtilisin protease. This experiment 
provides additional  support that N-CAM and the C1H3 pro- 
tein  are  immunologically  identical.  However,  the  yield  of 
25,000-mol-wt fragment from N-CAM appears to be lower 
than from protein immunopurified with the C~H3 MAb. This 
may therefore  raise the possibility that  only a  subset  of N- 
CAM contains a  heparin-binding  domain,  with the anti-N- 
CAM MAb immunopurifying less of  this subset than the Cj H3 
MAb. 
Role of Heparin-binding Domain in Cell- 
Substratum Adhesion 
To examine the role of the heparin-binding domain in cell- 
substratum adhesion, we were first interested in ascertaining 
whether the BIA3 MAb could inhibit heparin binding by the 
intact protein.  This would therefore indicate  that the  MAb 
recognizes the region of the molecule necessary for heparin 
binding. To test this possibility, we used a  [aH]heparin-bind- 
ing assay that was originally used to demonstrate that N-CAM 
possessed a heparin-binding domain (6). In initial studies, the 
BIA3 MAb preparation also contained a heparin-binding com- 
ponent, which probably resulted from other protein compo- 
nents  in the ascites  fluid.  We therefore  passed  BIA3 ascites 
fluid over heparin-agarose,  with the isolated MAb retaining 
activity (data not shown). When this MAb is incubated with 
N-CAM protein, and the N-CAM protein is then incubated 
with [3H]heparin, binding of heparin to the protein is inhib- 
ited (Table I). We have previously shown that the CIH3 MAb 
does not inhibit heparin binding (6),  which indicates that the 
BIA3 MAb  specifically  inhibits  [3H]heparin  binding  to  N- 
CAM. 
Since the BIA3 MAb inhibits heparin binding to N-CAM, 
this MAb can be used as a probe to determine the role of this 
structural  domain  in  mediating  cell-substratum  adhesion. 
Several  approaches  were  used  to  ascertain  if the  heparin- 
binding domain is required for cell-substratum adhesion. The 
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N-CAM by subtilisin protease.  10-ug aliquots 
ofimmunopurified N-CAM were incul ~ated 10 
min (a and d) or 20 min (b and e) with 1:100 
enzyme to substrate  of protease,  or 45  min 
with  1:50 enzyme to substrate  of protease (c 
and f). The digested N-CAM protein was then 
electrophoresed  on a 9%  polyacrylamide  gel, 
transferred to nitrocellulose, and analyzed by 
immunoblotting with CIH3 MAb (a-c) or BIA3 
MAb (d-f). 
Table I. Inhibition of  [3H]Heparin Binding to N-CAM by the 
BIA3 Monoclonal Antibody 
Percentage of 
Treatment  cpm bound 
No protein  0.4 _+ 0.0 
B~A3 MAb  2.2 _+ 0.3 
N-CAM  11.6 _+ 1.0 
N-CAM + B~A3 MAb  5.7 _+ 0.7 
Mean of two experiments  __.  SD conducted  in duplicate.  Input radioactivity 
represented  20,000 cpm  of [3H]heparin excluded  from  a  Sephadex  G-100 
column.  100 ug/ml of N-CAM protein was incubated 30 min with 200 ug/ml 
of B~A3 ascites fluid excluded  from a heparin-agarose  column.  [3H]Heparin 
was then added and incubated for 30 min, followed by binding to nitrocellulose 
(6). The samples were washed three times with PBS and counted. 
first approach was to immobilize intact N-CAM protein  or 
the heparin-binding domain on glass surfaces. The advantage 
of this assay system is that only one protein component can 
be analyzed, in contrast to adherons,  which are complex in 
molecular composition (31). We have previously shown that 
retinal cells will attach to N-CAM protein covalently coupled 
to glass (5,  6).  In the present experiment we were interested 
in  determining  if retinal  cells  would  bind  to  the  heparin- 
binding  domain,  which  would  imply  that  the  interaction 
between  cell  surface  heparan  sulfate  proteoglycan  and  N- 
CAM in the matrix can promote cell attachment.  As shown 
in Fig. 6, retinal cells attach to N-CAM covalently coupled to 
the glass surface, and this attachment is inhibited when retinal 
cells are incubated with the 25,000-mol-wt fragment or C~H3 
Fab fragments.  It can also be seen that the B~Aa MAb does 
not inhibit cell binding when incubated with the substratum, 
and  also does  not  prevent  cell  attachment  when  incubated 
with retinal  cells before the adhesion assay.  However, when 
B~A3  Fab  fragments are  present  in  the  medium  during the 
adhesion assay, cell attachment is inhibited. These data imply 
that the B~A3 MAb binds to the cell surface and substratum 
with  low affinity,  and  must  be  present  during the  assay  to 
competitively inhibit cell attachment. These data also confirm 
our  earlier  observations  that  the  interaction  between  cell 
surface  heparan  sulfate  proteoglycan  and  N-CAM  in  the 
matrix is required for neural cell-substratum adhesion. 
When derivatized vials are coated with the 25,000-mol-wt 
fragment (in molar ratios comparable to the intact protein), 
cell attachment  is also observed (Fig.  7).  The percentage of 
cells that bind  to the  heparin-binding domain  is  similar  to 
intact  N-CAM, which implies  that  the  25,000-mol-wt frag- 
ment and N-CAM bind to the glass surface with equal effi- 
ciency.  This  cell  binding  is  partially  inhibited  when  B~A3 
MAb is incubated with vials coated with the 25,000-mol-wt 
fragment,  and  addition  of heparin  or  an  antiserum  raised 
against a retinal cell surface heparan sulfate proteoglycan (29) 
prevents cell-substratum adhesion to the 25,000-mol-wt frag- 
ment. The CIH3 MAb also does not inhibit cell attachment 
under these assay conditions when the MAb is incubated with 
retinal  cells (data not shown), which suggests that the CIH3 
MAb inhibits cell-substratum adhesion by binding to a  sec- 
ond functional domain, presumed to be the cell-binding do- 
main. These data thus suggest that the isolated 25,000-mol- 
wt  fragment  has  sufficiently  high  affinity  for  cell  surface 
heparan  sulfate  to  yield  stable  cell-to-substratum  adhesion. 
These data also imply that the B~A3 MAb binds with higher 
affinity  to  the  heparin-binding  domain  than  to  the  intact 
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Figure 6.  Role of heparin-binding  domain in attachment of retinal 
cells to an N-CAM substratum. Glass scintillation vials were deriva- 
tized with 3-aminopropyltriethoxy silane (22, 23) and coated with 20 
ug/ml of immunopurified  N-CAM. Nonspecific cell attachment was 
determined using vials coated with albumin, and additional binding 
sites on N-CAM coated vials were blocked with Earle's balanced salt 
solution containing  0.2% albumin. Nonspecific cell binding  was also 
reduced by including 125/~g/ml of chondroitin sulfate in the assay 
medium (6). Metabolically labeled day  12  retinal  cells were then 
added to the vials for l h at 37"C. The effect of anti-N-CAM MAbs 
or the 25,000-mol-wt heparin-binding  fragment on cell attachment 
was examined by incubating labeled retinal cells with 0.5 mg/ml of 
C~H3 or B~A3 Fab fragments or  l0 ug/ml of the heparin-binding 
fragment for l h at 4"C. The cells were then washed twice and added 
to the coated vials. The effect of the B~A3 MAb on cell attachment 
was also assessed by incubating N-CAM-coated  vials with 0.5 mg/ 
ml of BIA3 Fab for  1 h at room temperature.  The vials were then 
washed and used in the adhesion assay. Alternatively, N-CAM-coated 
vials were incubated with 0.3 mg/ml of B~A~ Fab fragments, and this 
antibody remained  in the medium during the cell adhesion assay, 
which was donducted  using retinal  cells incubated with  B~A3 Fab 
fragments as previously described. Cell attachment was quantitated 
by dissolving bound cells in Triton X-100 and measuring isotope 
content. 
protein, since after incubation of this antibody with the sub- 
stratum, followed by washing, the B~A3 MAb can still inhibit 
cell attachment (Fig.  7).  This effect was  not observed with 
substrata was comprised of intact N-CAM (Fig. 6). These data 
also indicate that multiple mechanisms are involved in the 
promotion of neural cell-substratum adhesion, with the mul- 
tifunctional N-CAM protein playing an integral role in this 
process. 
Since we have shown previously that retinal cells attach to 
adherons in vitro, we were interested in demonstrating that 
the heparin-binding domain of N-CAM is required for this 
process.  To investigate this possibility, retinal cell adherons 
were adsorbed onto plastic petri dishes. As shown in Fig. 8, 
retinal cells attach to dishes coated with adheron protein, but 
not to  uncoated plastic.  Attachment of retinal cells to ad- 
heron-coated dishes is inhibited ~50-70% by the CjH3 MAb 
(3, 4), and likewise cell binding is inhibited 30-40% by the 
B~A3 MAb (Fig.  8).  We have previously demonstrated that 
binding of heparan sulfate to N-CAM induces a  conforma- 
tional change in the protein (6), and have postulated that this 
conformational change is required for  homophilic interac- 
tions involving  N-CAM. We therefore postulate that the BIA3 
antibody prevents cell-to-substratum attachment by prevent- 
ing this conformational change. It can also be seen that the 
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Figure  7.  Retinal  cell attachment to the  purified  heparin-binding 
domain of N-CAM. Glass scintillation vials were derivatized as de- 
scribed in Fig. 7 and coated with 3 #g of the 25,000-mol-wt heparin- 
binding  fragment. Nonspecific cell attachment was blocked by incu-- 
bating vials with Earle's balanced salt solution-0.2% albumin  and by 
including chondroitin sulfate (125 #g/ml) in the medium.  Cell at- 
tachment to the vials was measured using metabolically labeled day 
12 retinal cells as described under Materials and Methods. The effect 
of anti-beparan sulfate proteoglycan antiserum (aHSPG; 29) on cell 
adhesion  was  examined  by incubating retinal  cells with  a  1:100 
dilution of the antiserum for 1 h at 4"C. The effect of the B~A3 MAb 
on cell attachment was examined by incubating  the coated vials with 
0.5 mg/ml of BIA3 Fab fragments for 1 h at room temperature. The 
vials were then washed twice and used in the adhesion assay. The 
effect of heparin on cell binding  was assessed by including 50 ug/ml 
of heparin in the assay medium. Cell attachment was quantitated as 
described in Fig. 6.  The data  are  shown  as  two different  sets of 
experiments, conducted  in duplicate  at least three  times. The un- 
bound fraction is protein obtained  by digesting N-CAM with subtilisin 
protease, and which is then not retained on a heparin-agarose col- 
umn. 
BIA3  MAb once again does not significantly inhibit cell at- 
tachment when bound to adherons, and then washed from 
the substratum, yet the 25,000-mol-wt heparin-binding  frag- 
ment, when incubated with retinal cells, impairs cell attach- 
ment to adherons (Fig. 8). These data imply that the heparin- 
binding  domain of matrix N-CAM is necessary for retinal cell 
interactions with the extracellular matrix. However, as shown 
previously, the  BjA3  MAb  must  be  present  in  the  assay 
medium in order to inhibit cell attachment to intact N-CAM. 
Discussion 
In the present study we have investigated  the role ofa heparin- 
binding domain from the  170,000-mol-wt CIH3 polypeptide 
in promoting neural cell-substratum  adhesion. Previous stud- 
ies in our laboratory have demonstrated that the C~H3 MAb 
inhibits cell attachment to  the substratum when incubated 
with either cells or the substratum, which indicates that neural 
cell-substratum adhesion occurs via a  homophilic binding 
mechanism (4-6).  The interaction between heparan sulfate 
and the  170,000-mol-wt protein is also required for cell at- 
tachment since an antiserum to a cell surface heparan sulfate 
proteoglycan disrupts cell binding (6). We therefore proposed 
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Figure 8. Role of heparin-binding domain in cell binding  to adherons. 
35-mm plastic petri dishes were coated with 25 ~g of retina adheron 
protein, and  nonspecific binding sites were blocked with Earle's 
balanced salt solution containing 0.2% albumin. Mechanically dis- 
sociated day 12 retinal cells were then labeled with [3SS]methionine 
and incubated with the dishes for 1  h at 37°C. The role of  the heparin- 
binding domain of  N-CAM in promoting  cell attachment to adherons 
was examined by incubating aliquots of retinal cells with 0.5 mg/ml 
of B~A3 Fab fragments or 10 ~g/ml of the heparin-binding domain 
for  1 h at 4°C. The  cells were then washed twice and  added to 
adheron-coated dishes. Adheron-coated dishes were also incubated 
with B~A3 Fab fragments (0.5 mg/ml) for 1 h at room temperature, 
washed twice, and incubated with labeled retinal cells. After incuba- 
tion, dishes were swirled gently to dislodge weakly adherent cells, the 
medium was aspirated, and bound cells were dissolved in Triton X- 
100 in order to measure isotope content. 
that the binding of heparan sulfate to 170,000-mol-wt protein 
in the extracellular  matrix induces a conformational change 
in the protein, and this conformational change modulates the 
binding affinity of the protein (6). In this regard  neural cell- 
substratum adhesion is similar to cell attachment involving 
fibronectin, since  fibroblasts  attach to their matrix via pro- 
tein-protein and protein-glycosaminoglycan  interactions (15, 
16, 25, 37). Insight into the mechanism of fibronectin-medi- 
ated cell attachment has also been obtained by the isolation 
of specific structural and functional domains of the molecule, 
which are present in the intact molecule as protease-resistant 
fragments (22, 26,  38). Therefore, we were interested  in de- 
termining  whether  a  heparin-binding  domain  from  the 
170,000-mol-wt  protein  could  be  generated,  which  would 
permit us to characterize its  role  in  mediating neural cell- 
substratum adhesion. 
One  important  conclusion  that  can  be  made  from  the 
present  study  is  that  the  170,000-mol-wt  CIH3  protein  is 
immunologically identical  to N-CAM, as shown by immu- 
noblotting and immunoprecipitation analysis.  Although the 
CIH3 MAb can adsorb most N-CAM molecules (recognized 
by an anti-N-CAM MAb) from solution,  there appear to be 
subtle  differences  in  the  molecules  these  MAbs  recognize 
when the MAbs are used  to immunopurify their respective 
antigens.  For example, the predominant polypeptide immu- 
nopurified  from  brain  tissue  with  the  C~H3 MAb  is  the 
170,000-mol-wt  form of N-CAM, with smaller  amounts of 
the 140,000- and 120,000-mol-wt  proteins present.  However, 
the anti-N-CAM MAb immunopurifies approximately similar 
amounts of the three N-CAM components. Since both MAbs 
bind all three N-CAM components by immunoblotting pro- 
cedures, these results may arise due to differences in affinities 
for individual N-CAM components. For example,  the CIH3 
MAb may display a higher affinity towards the higher molec- 
ular weight N-CAM component, but is capable of binding all 
three  components.  Thus,  this  MAb  would  immunopurify 
greater amounts of the higher molecular weight component. 
The immunological identity between the CiH3 protein and 
N-CAM is of interest,  since it demonstrates a novel function 
for the N-CAM molecule.  N-CAM has been previously shown 
to  mediate  neuron-neuron  (33)  and  neuron-muscle  (11) 
adhesion, and recently has been shown to be present on glial 
cells (18, 20) and to participate in neuron-glia cell adhesion 
(18).  Our  data  indicate  that  N-CAM  contains  a  heparin- 
binding domain that is required for cell attachment to retinal 
cell extracellular  matrix material.  This is therefore the first 
evidence suggesting that N-CAM is a multifunctional protein. 
These data also imply that the heparin-binding domain may 
modulate  the  homophilic binding  between  N-CAM  mole- 
cules.  In addition, previous studies  have demonstrated that 
retinal  ganglion cell outgrowth occurs along glial endfeet in 
the optic tract and is mediated by N-CAM (32). In light of 
the  evidence that  neurite  outgrowth can  be  promoted  by 
heparin-binding domains  of extracellular  matrix  molecules 
(8, 24), it is promising to speculate  that glial endfeet contain 
a subset of N-CAM molecules that possess a heparin-binding 
domain.  Recent studies  in  several  laboratories  suggest that 
distinct subsets of N-CAM are present on different  classes of 
cells in the nervous system (18, 20, 35). Immunocytochemical 
staining  of developing nervous tissue  with  the  BIA3 MAb 
could provide information regarding whether this  MAb rec- 
ognizes a subset of N-CAM. 
The role of N-CAM in promoting neural cell-substratum 
adhesion was first demonstrated using the C~H3 MAb, with 
the MAb inhibiting the binding of retinal cells to adherons 
(4). Adherons are complexes of proteins and glycosaminogly- 
cans that  are  secreted  by neural  cells  in  culture,  and  thus 
resemble  extracellular  matrix material in molecular compo- 
sition  (31). As shown in previous studies  in our laboratory, 
the protein  now recognized as  N-CAM is a  component of 
adherons (4, 5), and the binding of  the CIH3 MAb to adherons 
partially inhibits cell attachment. Cell-adheron binding is also 
inhibited  by heparin  or  heparan  sulfate  (29,  31), and  the 
binding of retinal cells to a substratum of  N-CAM is inhibited 
by  heparan  sulfate  (6). These  data  implied  that  N-CAM 
contained a  heparin-binding domain, which has been  con- 
firmed in the present study. The heparin-binding domain, a 
25,000-mol-wt fragment, has been purified and partially  in- 
hibits cell attachment to adherons, but abolishes  cell binding 
to an  N-CAM substratum.  These  data  suggest that  not all 
retinal  cells binding to adherons in vitro are  binding to N- 
CAM, which is consistent with our observation that the C~H3 
MAb  does  not  completely  inhibit  cell-adheron  binding. 
Schubert and his co-workers have identified  another adheron 
component, called  purpurin, which is also involved in cell- 
adheron binding (30). Antibodies against this molecule inhibit 
adhesion only 40-50% (30), and the antigen is only present 
on a subpopulation of adherons. These data suggest that cell 
attachment to adherons occurs by multiple mechanisms, with 
several molecules being capable of binding subpopulations of 
neural cells. It remains to be determined whether the inhibi- 
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Figure 9.  Schematic diagram depicting a  possible model for neural 
cell-substratum adhesion,  based  on  current  experimental observa- 
tions. In A, the model shows that N-CAM undergoes a conformational 
change after binding of heparan sulfate (6), and homophilic binding 
between N-CAM molecules results in cell attachment to the matrix. 
Cell attachment does not occur under conditions shown in B  (i.e., 
CjH3  MAb has been  bound  to  cell  surface N-CAM,  which  is not 
diagrammed) since the interaction between cell surface heparan sul- 
fate and N-CAM is weak.  Cell attachment does occur in C, which 
implies that the isolated heparin-binding domain has a higher affinity 
for heparan sulfate. Possible mechanisms for the inhibition of cell- 
substratum adhesion by the C~H3 and B~A3 MAbs (represented by 
solid  circles)  or  the  heparin-binding  domain  of N-CAM  are  also 
depicted.  It is proposed that  the CIH3  MAb recognizes an epitope 
that is necessary for homophilic binding between N-CAM molecules. 
In contrast, the B~A3 MAb or heparin-binding domain prevent hep- 
aran  sulfate  binding  to  N-CAM,  preventing  the  conformational 
change in the N-CAM protein that allows homophilic binding and 
cell attachment. 
tory effect of the C]H3 MAb and anti-purpurin antibody will 
be additive, resulting in complete disruption of cell attach- 
ment. 
Since it is apparent that adherons are complex structures, 
it is more feasible to assess the role of a particular molecule 
in cell-substratum adhesion by coupling that molecule to an 
inert surface. When N-CAM is coupled to glass surfaces the 
CtH3  MAb and the 25,000-mol-wt heparin-binding domain 
inhibit cell attachment when incubated with retinal cells. The 
B~A3 MAb also inhibits cell attachment when included in the 
assay medium and incubated with the retinal cells. When a 
substratum  is  prepared using  the  25,000-mol-wt  fragment, 
cells attach to the substratum, and this binding is inhibited 
by the BIA3 MAb, heparin, or the anti-heparan sulfate pro- 
teoglycan  antiserum.  The  25,000-mol-wt  heparin-binding 
fragment of N-CAM therefore represents a distinct functional 
domain that can promote neural cell attachment. A scheme 
that summarizes our observations to date is shown in Fig. 9. 
We envisage that intact N-CAM protein containing the hep- 
aran-binding domain promotes cell attachment to the matrix 
by first binding cell surface heparan sulfate proteoglycan. This 
binding of heparan sulfate to N-CAM results in a conforma- 
tional change in the protein, which then allows homophilic 
binding between N-CAM molecules to occur. It is this binding 
mechanism that results in stable cell attachment. Binding of 
cell  surface heparan  sulfate to N-CAM  in the  extracellular 
matrix is too weak to generate a stable cell-to-matrix attach- 
ment, even though cells can bind to the 25,000-mol-wt hep- 
aran domain, which binds this proteoglycan with higher affin- 
ity. These data are consistent with our previous observations 
that the C~H3 MAb inhibits cell-substratum adhesion but not 
heparin binding, and that heparan sulfate or antibodies that 
block heparan sulfate-N-CAM  binding inhibit  cell-substra- 
tum adhesion. 
In conclusion, in the present study we have shown that the 
170,000-mol-wt CIH3 protein is immunologically identical to 
N-CAM. We have also isolated the B~A3 MAb which recog- 
nizes the heparin-binding domain of N-CAM, and this MAb 
inhibits the binding of heparin to N-CAM. We have identified 
a  25,000-mol-wt  heparin-binding  domain derived  from N- 
CAM, and this domain promotes cell attachment when cou- 
pled to glass surfaces, as well as inhibiting cell-adheron bind- 
ing when bound to retinal cells.  Thus, N-CAM represents a 
multifunctional protein that contains both cell- and heparin- 
binding domains. 
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